The results suggested that there is a strong association between rs4143815 C > G and the cancer risks (G vs. C: OR = 1.386, 95% CI: 1.132-1.696, p = 0.002; GG vs. CG + CC: OR = 1.843 95% CI: 1.300-2.613, p = 0.002; GG + CG vs. CC: OR = 1.280, 95% CI: 1.040-1.576, p = 0.020).
The results suggested that there is a strong association between rs41</span>43815 C > G and the cancer risks (G vs. C: OR = 1.386, 95% CI: 1.132-1.696, p = 0.002; GG vs. CG + CC: OR = 1.843 95% CI: 1.300-2.613, p = 0.002; GG + CG vs. CC: OR = 1.280, 95% CI: 1.040-1.576, p = 0.020).
In conclusions, the results of this meta-analysis have revealed an association between <i>PD-1</i> rs2227981, rs11568821, rs7421861, as well as <i>PD-L1</i> rs4143815 polymorphisms and overall cancer susceptibility.
In conclusions, the results of this meta-analysis have revealed an association between <i>PD-1</i> rs2227981, rs11568821, rs7421861, as well as <i>PD-L1</i> rs4143815 polymorphisms and overall cancer susceptibility.
In addition, the CGG haplotype in PD-L1 associated with T1D</span> (constructed from rs822342, rs2297137 and rs4143815 polymorphisms) showed an OR = 1.44 [1.08 to 1.93].
Our results indicate that rs4143815 of PD-L1 is significantly associated with T1DM and may serve as a new biomarker to predict the T1DM susceptibility.
Our results indicated that three functional polymorphisms (rs2297136, rs4143815 and rs17718883) of the PD-L1 gene were associated with HCC risk and prognosis, suggesting that genetic variants of PD-L1 polymorphisms might be a possible prognostic marker for the prediction of HCC risk and development.
None of the currently studied SNPs, PD-1 rs2227981 and rs10204525, PD-L1 rs1970000 and PD-L2 rs7854303, are associated with the susceptibility to Behcet's disease in a Chinese Han population.
Dual‑luciferase reporter assays showed that rs2297136 and rs4742098 in the B7‑H1 3'‑UTR contributed to the occurrence of NSCLC through disrupting the interaction between miR‑296‑5p, miR‑138 and B7‑H1 mRNA.
Data revealed that the rs2297136 (C > T) SNP TT (p = 0.03) and rs4143815 (C > G) SNP GG genotypes (p < 0.001) were associated with significantly increased risks of HCC.
PD-L1 rs2890658 A/C SNP might be used as risk marker of the susceptibility to ESCC for the Han nationality in a high-incidence population from Northern China.
No association was found between rs2890658 (A > C) SNP and HCC risk and this risk was significantly decreased in individuals with the rs17718883 SNP CG + GG genotype (p < 0.001).
We evaluated the frequency of alleles and genotypes of <i>IL-10</i> (rs3024496, rs1800872), <i>IL-10RA</i> (rs3135932), <i>IL-10RB</i> (rs2834167), <i>PD-1</i> (rs2227982, rs10204525), <i>PD-L1</i> (rs4143815), <i>PD-L2</i> (rs7854413), and single-nucleotide polymorphisms (SNPs) in 103 patients with chronic pathology (CP), such as elephantiasis or hydrocele and 106 endemic normal (EN) individuals from a South Indian population living in an area endemic for LF.
We evaluated the frequency of alleles and genotypes of <i>IL-10</i> (rs3024496, rs1800872), <i>IL-10RA</i> (rs3135932), <i>IL-10RB</i> (rs2834167), <i>PD-1</i> (rs2227982, rs10204525), <i>PD-L1</i> (rs4143815), <i>PD-L2</i> (rs7854413), and single-nucleotide polymorphisms (SNPs) in 103 patients with chronic pathology (CP), such as elephantiasis or hydrocele and 106 endemic normal (EN) individuals from a South Indian population living in an area endemic for LF.
A polymorphism in the <i>PDL1</i> gene (rs4143815) was the unique potential genetic variant of 10 year BCR (training set: <i>p</i> = 0.003, HR (95% CI) = 0.58 (0.41-0.83); replication set: <i>p</i> = 0.063, HR (95% CI) = 0.52 (0.26-1.04)) that was significantly associated with 5 year BCR (training set: <i>p</i> = 0.009, HR (95% CI) = 0.59 (0.40-0.88); replication set: <i>p</i> = 0.036, HR (95% CI) = 0.39 (0.16-0.94)).No biomarkers of OS were replicated. rs4143815-<i>PDL1</i> arose as a new immunogenetic biomarker of BCR in PCa, giving new insights into the RT/immune system interaction, which could be potentially useful in new approaches using anti-PDL1 therapies for PCa.
Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C > G might increase the susceptibility to gastric cancer (G vs. C: OR = 1.842, 95% CI: 1.403-2.418, p < 0.001) and bladder cancer (G vs. C: OR = 2.015, 95% CI: 1.556-2.608, p < 0.001), and genotype GG carriers of PD-L1 rs4143815 C > G might have higher risks of HCC (GG vs. CG + CC: OR = 2.226 95% CI: 1.562-3.172, p < 0.001).
A polymorphism in the <i>PDL1</i> gene (rs4143815) was the unique potential genetic variant of 10 year BCR (training set: <i>p</i> = 0.003, HR (95% CI) = 0.58 (0.41-0.83); replication set: <i>p</i> = 0.063, HR (95% CI) = 0.52 (0.26-1.04)) that was significantly associated with 5 year BCR (training set: <i>p</i> = 0.009, HR (95% CI) = 0.59 (0.40-0.88); replication set: <i>p</i> = 0.036, HR (95% CI) = 0.39 (0.16-0.94)).No biomarkers of OS were replicated. rs4143815-<i>PDL1</i> arose as a new immunogenetic biomarker of BCR in PCa, giving new insights into the RT/immune system interaction, which could be potentially useful in new approaches using anti-PDL1 therapies for PCa.
Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C > G might increase the susceptibility to gastric cancer (G vs. C: OR = 1.842, 95% CI: 1.403-2.418, p < 0.001) and bladder cancer (G vs. C: OR = 2.015, 95% CI: 1.556-2.608, p < 0.001), and genotype GG carriers of PD-L1 rs4143815 C > G might have higher risks of HCC (GG vs. CG + CC: OR = 2.226 95% CI: 1.562-3.172, p < 0.001).